Moshe Talpaz
YOU?
Author Swipe
View article: Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study
Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study Open
Janus kinase inhibitor (JAKi) monotherapy, the standard of care for myelofibrosis (MF), improves splenomegaly and symptom burden but provides limited depth and durability of response. There is a significant unmet need for new combination s…
View article: Quantitative MRI Assessment of Bone Marrow Disease in Myelofibrosis: A Prospective Study
Quantitative MRI Assessment of Bone Marrow Disease in Myelofibrosis: A Prospective Study Open
MRI helped quantify macromolecular and cellular changes in the bone marrow of individuals with myelofibrosis, with increased apparent diffusion coefficient values correlating with biopsy-proven fibrosis.
View article: Understanding the Functional Dependence and Inhibition of the Bcl-2 Pro-Survival Proteins in a Wide Spectrum of Cancers toward Precision Medicine
Understanding the Functional Dependence and Inhibition of the Bcl-2 Pro-Survival Proteins in a Wide Spectrum of Cancers toward Precision Medicine Open
Introducing and integrating functional assays into clinical cancer care can further enhance the effectiveness of precision cancer medicine. Bcl-2 pro-survival proteins have emerged as promising targets across various cancers, with Venetocl…
View article: Fat Fraction MRI for Longitudinal Assessment of Bone Marrow Heterogeneity in a Mouse Model of Myelofibrosis
Fat Fraction MRI for Longitudinal Assessment of Bone Marrow Heterogeneity in a Mouse Model of Myelofibrosis Open
Background/Objectives: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by the replacement of healthy bone marrow (BM) with malignant and fibrotic tissue. In a healthy state, bone marrow is composed of approximately 60–70%…
View article: Effects of Calreticulin Mutations on HLA Class I Expression in Myeloproliferative Neoplasms
Effects of Calreticulin Mutations on HLA Class I Expression in Myeloproliferative Neoplasms Open
Calreticulin (CRT) is important for human leukocyte antigen (HLA) class I assembly. Somatic mutations of the CRT gene ( CALR ) in hematopoietic lineage cells cause myeloproliferative neoplasms (MPNs). Typically, MPN patient cells have one …
View article: Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials
Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials Open
Introduction Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life. Red blood cell transfusions form the basis of anemia management in myelofibrosis but depe…
View article: A deep learning aided bone marrow segmentation of quantitative fat MRI for myelofibrosis patients
A deep learning aided bone marrow segmentation of quantitative fat MRI for myelofibrosis patients Open
Purpose To automate bone marrow segmentation within pelvic bones in quantitative fat MRI of myelofibrosis (MF) patients using deep-learning (DL) U-Net models. Methods Automated segmentation of bone marrow (BM) was evaluated for four U-Net …
View article: Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results Open
Asciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP). The present final analysis of the phase 1, open-label, nonrandomized trial (NCT02081378) assessed the long-term safety, tolerab…
View article: A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia Open
Background Hepcidin, a central regulator of iron homeostasis, is pathologically elevated in patients with myelofibrosis (MF) and anemia. Chronic hepcidin elevation limits iron availability for red blood cell production and contributes to o…
View article: Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy - First Report from the Maestro Trial
Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy - First Report from the Maestro Trial Open
Introduction: Minimal residual disease (MRD) negativity has emerged as an important prognostic marker in multiple myeloma (MM), correlating with improved overall survival (OS). This study aims to optimize therapeutic outcomes and minimize …
View article: Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials
Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials Open
Introduction: Fedratinib (FEDR) is a Janus kinase 2 inhibitor shown to improve spleen size and symptoms for treatment-naive and post-ruxolitinib pts with myelofibrosis (MF). Some pts with MF treated with FEDR have elevated serum creatinine…
View article: Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib Open
ClinicalTrials.gov identifiers: NCT02515630, NCT01969838, NCT02101268, NCT04173494.
View article: Supplementary Figure S8 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S8 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
AVID200 induced similar decrements in the plasma levels of TGF-β in the three patients with and without platelet response
View article: Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Clinical info on the platelets-responsive and non-responsive patients
View article: Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Representativeness of Study Participants.
View article: Supplementary Figure S7 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S7 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Effects of AVID200 therapy on plasma TGFβ levels.
View article: Supplementary Figure S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
MPN-RC 118 phase 1b study schema
View article: Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Duration of treatment and response status.
View article: Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Baseline mutational profile of enrolled patients.
View article: Supplementary Table S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Patient listing of prior myelofibrosis treatment and time since discontinuation if known
View article: Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
PK data for Cycle 1 (first 24 hours only) for A) 180 mg/m2 dose level and B) 550 mg/m2 dose level during dose escalation phase I.
View article: Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Clinical info on the platelets-responsive and non-responsive patients
View article: Supplementary Figure S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Oncoprint Analysis of Serial Samples from Phase 1b Trial of AVID200
View article: Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Baseline mutational profile of enrolled patients.
View article: Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Representativeness of Study Participants.
View article: Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
PK data for Cycle 1 (first 24 hours only) for A) 180 mg/m2 dose level and B) 550 mg/m2 dose level during dose escalation phase I.
View article: Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Individual patient data for AUC, Cmax and Tmax for dose levels 1 and 2 (Lot A). Summary measures for DL 1 and DL2 are shown in red.
View article: Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Individual patient data for AUC, Cmax and Tmax for dose levels 1 and 2 (Lot A). Summary measures for DL 1 and DL2 are shown in red.